Abstract
Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.
Current Drug Targets
Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Volume: 19 Issue: 13
Author(s): Qun Zhou*
Affiliation:
- Protein Engineering, Biologics Research, Sanofi, Framingham, MA, 01701,United States
Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.
Abstract: Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
Export Options
About this article
Cite this article as:
Zhou Qun*, Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180308144313
DOI https://dx.doi.org/10.2174/1389450119666180308144313 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry The Role of Long Noncoding RNAs in Progression of Leukemia: Based on Chromosomal Location
MicroRNA Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
Current Radiopharmaceuticals Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens
Current Medicinal Chemistry Recent Developments in Taxane Drug Delivery
Current Drug Delivery The Cell Engraftment Hypothesis of Cardiac Repair
Current Stem Cell Research & Therapy Clinical Presentation, Outcome and Risk Factors of Late-Onset Non- Infectious Pulmonary Complications After Allogeneic Stem Cell Transplantation
Current Stem Cell Research & Therapy Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical Thioacetic Acid Addition
Current Bioactive Compounds Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future
Current Molecular Medicine Osteoimmunology and Beyond
Current Medicinal Chemistry Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets <i>In silico</i> Identification of HDAC Inhibitors for Multiple Myeloma: A Structure-based Virtual Screening, Drug Likeness, ADMET Profiling, Molecular Docking, and Molecular Dynamics Simulation Study
Letters in Drug Design & Discovery Editorial [Hot Topic: Immunomodulators in Medicinal Chemistry and Drug Discovery (Guest Editor: Dr. Athanasia Mouzaki)]
Current Topics in Medicinal Chemistry Synthesis and Biological Activities of Oxadiazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry